Home
ONCO

ONCO

Onconetix Inc.

as of 12-12-2025 4:00pm EST

$2.30

$0.01

-0.43%

Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Chart Type:

Time Range:

Founded:	2018	Country:	United States
Employees:	N/A	City:	CINCINNATI
Market Cap:	4.3M	IPO Year:	2022
Target Price:	N/A	AVG Volume (30 days):	37.9K
Analyst Decision:	N/A	Number of Analysts:	N/A
Dividend Yield:	N/A	Dividend Payout Frequency:	N/A
EPS:	-89.08	EPS Growth:	N/A
52 Week Low/High:	$2.10 - $179.35	Next Earning Date:	11-13-2025
Revenue:	$1,223,751	Revenue Growth:	-34.58%
Revenue Growth (this year):	N/A	Revenue Growth (next year):	N/A

AI-Powered ONCO Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 3 days ago

AI Recommendation

hold

Model Accuracy: 78.95%

78.95%

Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

View Full ONCO Forecast & Prediction with Hourly Data

Compare ONCO vs Leading Stocks

See how ONCO stacks up against similar companies in the market

Share on Social Networks:

Tools & Resources

Enhance your trading experience with our free tools

Free ONCO Stock Widget

Embed our interactive stock ticker widget on your website for real-time updates.

Free Tool

Stock Alerts on Telegram

Get instant notifications, market insights, and expert analysis delivered to your phone.

Live Updates

Disclaimer

The information presented on this page, "ONCO Onconetix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.